APLIF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Dec 11 closing price
62 days until earnings call
GENFF
Price
$0.06
Change
+$0.02 (+50.00%)
Updated
Dec 13 closing price
Ad is loading...

APLIF vs GENFF

Header iconAPLIF vs GENFF Comparison
Open Charts APLIF vs GENFFBanner chart's image
Appili Therapeutics
Price$0.03
Change-$0.00 (-0.00%)
Volume$171.8K
CapitalizationN/A
Genflow Biosciences
Price$0.06
Change+$0.02 (+50.00%)
Volume$100K
CapitalizationN/A
APLIF vs GENFF Comparison Chart
Loading...
APLIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GENFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLIF vs. GENFF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLIF is a Buy and GENFF is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (APLIF: $0.03 vs. GENFF: $0.06)
Brand notoriety: APLIF and GENFF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLIF: 139% vs. GENFF: 1501%
Market capitalization -- APLIF: $3.41M vs. GENFF: $6.77M
APLIF [@Biotechnology] is valued at $3.41M. GENFF’s [@Biotechnology] market capitalization is $6.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLIF’s FA Score shows that 1 FA rating(s) are green whileGENFF’s FA Score has 0 green FA rating(s).

  • APLIF’s FA Score: 1 green, 4 red.
  • GENFF’s FA Score: 0 green, 5 red.
According to our system of comparison, APLIF is a better buy in the long-term than GENFF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLIF’s TA Score shows that 5 TA indicator(s) are bullish while GENFF’s TA Score has 1 bullish TA indicator(s).

  • APLIF’s TA Score: 5 bullish, 3 bearish.
  • GENFF’s TA Score: 1 bullish, 1 bearish.
According to our system of comparison, APLIF is a better buy in the short-term than GENFF.

Price Growth

APLIF (@Biotechnology) experienced а -7.74% price change this week, while GENFF (@Biotechnology) price change was +42.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

APLIF is expected to report earnings on Feb 18, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GENFF($6.78M) has a higher market cap than APLIF($3.41M). GENFF YTD gains are higher at: 151.250 vs. APLIF (-2.868).
APLIFGENFFAPLIF / GENFF
Capitalization3.41M6.78M50%
EBITDA-1.27MN/A-
Gain YTD-2.868151.250-2%
P/E RatioN/AN/A-
Revenue827KN/A-
Total Cash301KN/A-
Total Debt10.1MN/A-
TECHNICAL ANALYSIS
Technical Analysis
APLIFGENFF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
40%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
43%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
View a ticker or compare two or three
Ad is loading...
APLIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GENFF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRGPX22.46N/A
N/A
Nuveen Mid Cap Growth Premier
ITEAX10.37-0.05
-0.48%
VY® T. Rowe Price Equity Income A
FEGRX68.88-0.44
-0.63%
First Eagle Global R6
LFGOX38.67-0.34
-0.87%
Lord Abbett Focused Growth F3
CSMFX26.29-0.31
-1.17%
Carillon Scout Mid Cap C

APLIF and

Correlation & Price change

A.I.dvisor tells us that APLIF and GENFF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APLIF and GENFF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLIF
1D Price
Change %
APLIF100%
N/A
GENFF - APLIF
25%
Poorly correlated
N/A
CTCX - APLIF
21%
Poorly correlated
+6.09%
ARTH - APLIF
12%
Poorly correlated
+16.67%
ARGNF - APLIF
10%
Poorly correlated
N/A
AAVXF - APLIF
9%
Poorly correlated
N/A
More

GENFF and

Correlation & Price change

A.I.dvisor tells us that GENFF and APLIF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GENFF and APLIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENFF
1D Price
Change %
GENFF100%
N/A
APLIF - GENFF
27%
Poorly correlated
N/A
TOVX - GENFF
25%
Poorly correlated
+1.71%
VRCA - GENFF
23%
Poorly correlated
-2.51%
SGMT - GENFF
10%
Poorly correlated
+3.66%
OCS - GENFF
6%
Poorly correlated
+2.05%
More